Literature DB >> 16269656

Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF.

Oliver Krysiak1, Anja Bretschneider, Enhong Zhong, Jessie Webb, Hartmut Hopp, Stefan Verlohren, Norbert Fuhr, Malgorzata Lanowska, Andreas Nonnenmacher, Roland Vetter, Joachim Jankowski, Martin Paul, Gilbert Schönfelder.   

Abstract

Neutrophil activation and increased migration is associated with preeclampsia and is resolved after delivery. Preeclampsia is an inflammatory disorder where altered levels of vascular endothelial growth factor (VEGF) and the circulating soluble fms-like tyrosine kinase 1 (sFlt-1) have a pathogenic role. VEGF, by binding to FLT-1, induces leukocytic chemotaxis. We studied expression and function of FLT-1 in maternal neutrophils during preeclampsia and normal pregnancies. Analysis of maternal neutrophils showed the relationship between FLT-1 expression and week of gestation. Preeclamptic women express lower FLT-1 and sFLT-1 in neutrophils. In contrast, serum levels of sFLT-1 in patients with preeclampsia are increased and, therefore, inhibit upregulation of FLT-1 in neutrophils by neutralizing VEGF. VEGF-dependent FLT-1 expression is regulated by changing FLT-1-promoter activity. Promoter activity is decreased by sFLT-1. In vitro experiments demonstrated that migration of neutrophils is regulated by VEGF via FLT-1 and excess of sFLT-1. Thus, VEGF-dependent migration of neutrophils is decreased during preeclampsia as a consequence of excess circulating sFlt1. But, they still increase migration by fMLP and, therefore, migration of neutrophils from preeclamptic women is highly activated when compared with the normotensive group. In conclusion, besides being involved in inducing an antiangiogenic state in the serum, excess of sFLT-1 seems to prevent activated neutrophils from women with preeclampsia from additional migration by VEGF. We provide evidence that neutrophils may be involved in the pathophysiology of pregnancy-related hypertensive disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269656     DOI: 10.1161/01.RES.0000194324.29363.82

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

1.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

2.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Authors:  Daniel Menendez; Oliver Krysiak; Alberto Inga; Bianca Krysiak; Michael A Resnick; Gilbert Schönfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 3.  Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Michael J Ryan; Jeffrey S Gilbert; Sydney R Murphy; Joey P Granger
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

4.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

5.  Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro.

Authors:  G V Chaitanya; S E Franks; W Cromer; S R Wells; M Bienkowska; M H Jennings; A Ruddell; T Ando; Y Wang; Y Gu; M Sapp; J M Mathis; P A Jordan; A Minagar; J S Alexander
Journal:  Lymphat Res Biol       Date:  2010-09       Impact factor: 2.589

6.  RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway.

Authors:  Feng Wang; Mai Yamauchi; Masashi Muramatsu; Tsuyoshi Osawa; Rika Tsuchida; Masabumi Shibuya
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

7.  Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.

Authors:  Mary A Grummer; Jeremy A Sullivan; Ronald R Magness; Ian M Bird
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

Review 8.  Cellular immune responses in the pathophysiology of preeclampsia.

Authors:  Derek Miller; Kenichiro Motomura; Jose Galaz; Meyer Gershater; Eun D Lee; Roberto Romero; Nardhy Gomez-Lopez
Journal:  J Leukoc Biol       Date:  2021-04-13       Impact factor: 6.011

9.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.

Authors:  Guillermina Girardi; Dmitry Yarilin; Joshua M Thurman; V Michael Holers; Jane E Salmon
Journal:  J Exp Med       Date:  2006-08-21       Impact factor: 14.307

Review 10.  The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia.

Authors:  Pooneh Nikuei; Kianoosh Malekzadeh; Minoo Rajaei; Azim Nejatizadeh; Nasrin Ghasemi
Journal:  Iran J Reprod Med       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.